Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular Degeneration (nAMD) by many studies. Bevacizumab is the only available low-cost type of anti-VEGF drug currently in China. This study is a multi-center, randomized trial of Bevacizumab effective dose and safety for nAMD. This study is to explore the effective therapeutic approach that the majority of patients in China can bear establishing a suitable treatment for China.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
210
Bevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks
Bevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week
Xiaoxin Li
Beijing, Beijing Municipality, China
EDTRS visual acuity score
EDTRS visual acuity score is assessed at each timepoint for every group
Time frame: 0week(baseline), 6week, 12week, 18week, 24week, 30week, 36week, 42week, 48week
macular thickness in OCT
macular thickness is assessed at each timepoint for every group
Time frame: 0week(baseline), 6week, 12week, 18week, 24week, 30week, 36week, 42week, 48week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.